The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended new restriction on dronedarone (Multaq), Sanofi's embattled and controversial antiarrhythmic drug.

A trial of the drug Multaq, used to treat abnormal heart rhythm, has been halted over concerns of other heart-related side effects, drug maker Sanofi announced Thursday. Multaq, also known as ...

The heart drug Multaq continues to be approved for use in Canada, but Health Canada says reports of its connection to liver damage will be reviewed. On Friday, the U.S. Food and Drug Administration ...

The PALLAS trial of dronedarone (Multaq) for permanent AF has been stopped early, according to a press release (below) issued by Sanofi. PALLAS (Permanent Atrial fibriLLAtion outcome Study using ...

Multaq may have hit a snag. The atrial fibrillation drug from Sanofi-Aventis, whose 2009 U.S. launch got off to a slow start, is the subject of an impending "Dear Doctor" letter to inform physicians ...

PARIS, Nov 16 (Reuters) - Sanofi's irregular heart beat drug Multaq will no longer be reimbursed by the French health system from December, in a further setback to a medicine once seen as a ...

Multaq(R) Approved to Reduce the Risk of Cardiovascular Hospitalizationin Patients With Atrial Fibrillation or Atrial Flutter. PARIS, July 2 /PRNewswire/ -- - U.S Commercial Launch Planned for the ...

- Benefit-risk of Multaq remains unchanged in non-permanent AF patients - Paris, France - July 7, 2011 - Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the company has discontinued the ...

PARIS, August 29, 2010 /PRNewswire/ -- Sanofi aventis (EURONEXT: SAN and NYSE: SNY) announced today that the European Society of Cardiology (ESC) 2010 new Guidelines for the Management of Atrial ...

Before Sanofi-Aventis launched its heart drug Multaq, some analysts estimated revenues would top €3 billion. But 10 weeks into the launch, Multaq looks like a much more modest affair, according to a ...

STOCKHOLM, Aug 29 (Reuters) - Sanofi-Aventis's new heart rhythm drug Multaq should be considered as a first-line treatment option for patients with atrial fibrillation, a common arrhythmia, according ...